Enterprise Value
22.03M
Cash
30.77M
Avg Qtr Burn
-4.992M
Short % of Float
1.51%
Insider Ownership
47.45%
Institutional Own.
8.44%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EVOMELA (melphalan) Details MM (Multiple Myeloma) | Approved Quarterly sales | |
CNCT-19 (Anti-CD19) Details Non-Hodgkin lymphoma | Phase 2 Update | |
BI-1206 (Anti-FcyRIIB antibody) + rituximab Details Blood cancer, Cancer, Solid tumor/s, Non-Hodgkin lymphoma | Phase 1/2 Data readout | |
CB-5339 Details Multiple myeloma | Phase 1 Data readout |